-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, April 20, April 15th, NMPA official website updated the drug approval information, Xingqi Eye Medicine, Qilu Pharmaceutical and Jiangxi Kelun Pharmaceutical have all been approved for new eye drops; on April 16, Hengruizi The company Chengdu Shengdi Pharmaceutical has applied for the clinical trial of HR19034 eye drops 2.
4 category new drug and has been contracted.
.
.
Recently, there are good news in the ophthalmic preparation market, and the market potential of 7 billion is expected.
4 category new drug and has been contracted.
.
.
Recently, there are good news in the ophthalmic preparation market, and the market potential of 7 billion is expected.
Figure 1: Ophthalmic preparations recently approved for marketing
Source: NMPA official website
Moxifloxacin hydrochloride eye drops are mainly used for the treatment of bacterial conjunctivitis caused by sensitive microorganisms.
The original research company Novartis was approved to enter the country in 2018.
It is a new item in the 2019 National Medical Insurance Catalogue, and the scope of use is restricted in the 2020 National Medical Insurance Catalogue It is "restricted to second-line medication.
" The approval of domestic imitation products will usher in a blowout in 2021.
Earlier, Shanghai Xinyi Jinzhu Pharmaceutical, China Resources Zizhu Pharmaceutical, and Zhuhai Yisheng Biopharmaceuticals were approved to be listed in four types of imitations.
This time, Xingqi Eye Medicine and Kelun were approved.
After approval, a total of 5 domestic pharmaceutical companies were approved and deemed to have been reviewed.
Moxifloxacin eye drops were included in the fifth batch of national procurement reports circulated in the industry earlier, and this national procurement bid will be quite fierce.
The original research company Novartis was approved to enter the country in 2018.
It is a new item in the 2019 National Medical Insurance Catalogue, and the scope of use is restricted in the 2020 National Medical Insurance Catalogue It is "restricted to second-line medication.
" The approval of domestic imitation products will usher in a blowout in 2021.
Earlier, Shanghai Xinyi Jinzhu Pharmaceutical, China Resources Zizhu Pharmaceutical, and Zhuhai Yisheng Biopharmaceuticals were approved to be listed in four types of imitations.
This time, Xingqi Eye Medicine and Kelun were approved.
After approval, a total of 5 domestic pharmaceutical companies were approved and deemed to have been reviewed.
Moxifloxacin eye drops were included in the fifth batch of national procurement reports circulated in the industry earlier, and this national procurement bid will be quite fierce.
Figure 2: Sales of Brimonidine Tartrate Eye Drops
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Brimonidine tartrate eye drops are suitable for reducing the intraocular pressure of patients with open-angle glaucoma and ocular hypertension, and are listed in the national medical insurance catalog.
According to data from Menet.
com, the sales of brimonidine tartrate eye drops in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased in recent years.
the first half of 2020 for the first time to squeeze in ophthalmic products TOP20 list of preparations, the current market leader in the business for the United States Al build, market share of over 80% had earlier obtained approval of the domestic pharmaceutical enterprises, including the Hang Seng Nanjing, Beijing and Lunan pharmaceutical Department of En Lande Better Pharmaceuticals, Qilu Pharmaceuticals was approved according to 4 types of generics this time and was the first to pass the review.
According to data from Menet.
com, the sales of brimonidine tartrate eye drops in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased in recent years.
the first half of 2020 for the first time to squeeze in ophthalmic products TOP20 list of preparations, the current market leader in the business for the United States Al build, market share of over 80% had earlier obtained approval of the domestic pharmaceutical enterprises, including the Hang Seng Nanjing, Beijing and Lunan pharmaceutical Department of En Lande Better Pharmaceuticals, Qilu Pharmaceuticals was approved according to 4 types of generics this time and was the first to pass the review.
Figure 3: Chengdu Shengdi Medicine declares a new clinical drug
Source: CDE official website
According to data from Menet.
com, the sales scale of terminal ophthalmic preparations in Chinese public medical institutions in 2019 has risen to nearly 7 billion yuan.
In 2020, 13 domestic new products will be approved for marketing (according to the date of approval), and they have been approved since 2021.
There are also 8 new products on the market.
With the continuous efforts of domestic pharmaceutical companies, the market for ophthalmic preparations is also growing.
com, the sales scale of terminal ophthalmic preparations in Chinese public medical institutions in 2019 has risen to nearly 7 billion yuan.
In 2020, 13 domestic new products will be approved for marketing (according to the date of approval), and they have been approved since 2021.
There are also 8 new products on the market.
With the continuous efforts of domestic pharmaceutical companies, the market for ophthalmic preparations is also growing.
Source: NMPA official website, CDE official website, Mi Nei.
com data
com data
The review data statistics are as of April 19, if there are any errors or omissions, please correct me.
Medical Network, April 20, April 15th, NMPA official website updated the drug approval information, Xingqi Eye Medicine, Qilu Pharmaceutical and Jiangxi Kelun Pharmaceutical have all been approved for new eye drops; on April 16, Hengruizi The company Chengdu Shengdi Pharmaceutical has applied for the clinical trial of HR19034 eye drops 2.
4 category new drug and has been contracted.
.
.
Recently, there are good news in the ophthalmic preparation market, and the market potential of 7 billion is expected.
4 category new drug and has been contracted.
.
.
Recently, there are good news in the ophthalmic preparation market, and the market potential of 7 billion is expected.
Figure 1: Ophthalmic preparations recently approved for marketing
Source: NMPA official website
Moxifloxacin hydrochloride eye drops are mainly used for the treatment of bacterial conjunctivitis caused by sensitive microorganisms.
The original research company Novartis was approved to enter the country in 2018.
It is a new item in the 2019 National Medical Insurance Catalogue, and the scope of use is restricted in the 2020 National Medical Insurance Catalogue It is "restricted to second-line medication.
" The approval of domestic imitation products will usher in a blowout in 2021.
Earlier, Shanghai Xinyi Jinzhu Pharmaceutical, China Resources Zizhu Pharmaceutical, and Zhuhai Yisheng Biopharmaceuticals were approved to be listed in four types of imitations.
This time, Xingqi Eye Medicine and Kelun were approved.
After approval, a total of 5 domestic pharmaceutical companies were approved and deemed to have been reviewed.
Moxifloxacin eye drops were included in the fifth batch of national procurement reports circulated in the industry earlier, and this national procurement bid will be quite fierce.
The original research company Novartis was approved to enter the country in 2018.
It is a new item in the 2019 National Medical Insurance Catalogue, and the scope of use is restricted in the 2020 National Medical Insurance Catalogue It is "restricted to second-line medication.
" The approval of domestic imitation products will usher in a blowout in 2021.
Earlier, Shanghai Xinyi Jinzhu Pharmaceutical, China Resources Zizhu Pharmaceutical, and Zhuhai Yisheng Biopharmaceuticals were approved to be listed in four types of imitations.
This time, Xingqi Eye Medicine and Kelun were approved.
After approval, a total of 5 domestic pharmaceutical companies were approved and deemed to have been reviewed.
Moxifloxacin eye drops were included in the fifth batch of national procurement reports circulated in the industry earlier, and this national procurement bid will be quite fierce.
Figure 2: Sales of Brimonidine Tartrate Eye Drops
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Brimonidine tartrate eye drops are suitable for reducing the intraocular pressure of patients with open-angle glaucoma and ocular hypertension, and are listed in the national medical insurance catalog.
According to data from Menet.
com, the sales of brimonidine tartrate eye drops in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased in recent years.
the first half of 2020 for the first time to squeeze in ophthalmic products TOP20 list of preparations, the current market leader in the business for the United States Al build, market share of over 80% had earlier obtained approval of the domestic pharmaceutical enterprises, including the Hang Seng Nanjing, Beijing and Lunan pharmaceutical Department of En Lande Better Pharmaceuticals, Qilu Pharmaceuticals was approved according to 4 types of generics this time and was the first to pass the review.
According to data from Menet.
com, the sales of brimonidine tartrate eye drops in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased in recent years.
the first half of 2020 for the first time to squeeze in ophthalmic products TOP20 list of preparations, the current market leader in the business for the United States Al build, market share of over 80% had earlier obtained approval of the domestic pharmaceutical enterprises, including the Hang Seng Nanjing, Beijing and Lunan pharmaceutical Department of En Lande Better Pharmaceuticals, Qilu Pharmaceuticals was approved according to 4 types of generics this time and was the first to pass the review.
Figure 3: Chengdu Shengdi Medicine declares a new clinical drug
Source: CDE official website
According to data from Menet.
com, the sales scale of terminal ophthalmic preparations in Chinese public medical institutions in 2019 has risen to nearly 7 billion yuan.
In 2020, 13 domestic new products will be approved for marketing (according to the date of approval), and they have been approved since 2021.
There are also 8 new products on the market.
With the continuous efforts of domestic pharmaceutical companies, the market for ophthalmic preparations is also growing.
com, the sales scale of terminal ophthalmic preparations in Chinese public medical institutions in 2019 has risen to nearly 7 billion yuan.
In 2020, 13 domestic new products will be approved for marketing (according to the date of approval), and they have been approved since 2021.
There are also 8 new products on the market.
With the continuous efforts of domestic pharmaceutical companies, the market for ophthalmic preparations is also growing.
Source: NMPA official website, CDE official website, Mi Nei.
com data
com data
The review data statistics are as of April 19, if there are any errors or omissions, please correct me.
Medical Network, April 20, April 15th, NMPA official website updated the drug approval information, Xingqi Eye Medicine, Qilu Pharmaceutical and Jiangxi Kelun Pharmaceutical have all been approved for new eye drops; on April 16, Hengruizi The company Chengdu Shengdi Pharmaceutical has applied for the clinical trial of HR19034 eye drops 2.
4 category new drug and has been contracted.
.
.
Recently, there are good news in the ophthalmic preparation market, and the market potential of 7 billion is expected.
4 category new drug and has been contracted.
.
.
Recently, there are good news in the ophthalmic preparation market, and the market potential of 7 billion is expected.
Figure 1: Ophthalmic preparations recently approved for marketing
Source: NMPA official website
Moxifloxacin hydrochloride eye drops are mainly used for the treatment of bacterial conjunctivitis caused by sensitive microorganisms.
The original research company Novartis was approved to enter the country in 2018.
It is a new item in the 2019 National Medical Insurance Catalogue, and the scope of use is restricted in the 2020 National Medical Insurance Catalogue It is "restricted to second-line medication.
" The approval of domestic imitation products will usher in a blowout in 2021.
Earlier, Shanghai Xinyi Jinzhu Pharmaceutical, China Resources Zizhu Pharmaceutical, and Zhuhai Yisheng Biopharmaceuticals were approved to be listed in four types of imitations.
This time, Xingqi Eye Medicine and Kelun were approved.
After approval, a total of 5 domestic pharmaceutical companies were approved and deemed to have been reviewed.
Moxifloxacin eye drops were included in the fifth batch of national procurement reports circulated in the industry earlier, and this national procurement bid will be quite fierce.
The original research company Novartis was approved to enter the country in 2018.
It is a new item in the 2019 National Medical Insurance Catalogue, and the scope of use is restricted in the 2020 National Medical Insurance Catalogue It is "restricted to second-line medication.
" The approval of domestic imitation products will usher in a blowout in 2021.
Earlier, Shanghai Xinyi Jinzhu Pharmaceutical, China Resources Zizhu Pharmaceutical, and Zhuhai Yisheng Biopharmaceuticals were approved to be listed in four types of imitations.
This time, Xingqi Eye Medicine and Kelun were approved.
After approval, a total of 5 domestic pharmaceutical companies were approved and deemed to have been reviewed.
Moxifloxacin eye drops were included in the fifth batch of national procurement reports circulated in the industry earlier, and this national procurement bid will be quite fierce.
Figure 2: Sales of Brimonidine Tartrate Eye Drops
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Brimonidine tartrate eye drops are suitable for reducing the intraocular pressure of patients with open-angle glaucoma and ocular hypertension, and are listed in the national medical insurance catalog.
According to data from Menet.
com, the sales of brimonidine tartrate eye drops in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased in recent years.
the first half of 2020 for the first time to squeeze in ophthalmic products TOP20 list of preparations, the current market leader in the business for the United States Al build, market share of over 80% had earlier obtained approval of the domestic pharmaceutical enterprises, including the Hang Seng Nanjing, Beijing and Lunan pharmaceutical Department of En Lande Better Pharmaceuticals, Qilu Pharmaceuticals was approved according to 4 types of generics this time and was the first to pass the review.
Hospital Hospital Hospital Enterprise Enterprise EnterpriseAccording to data from Menet.
com, the sales of brimonidine tartrate eye drops in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have steadily increased in recent years.
the first half of 2020 for the first time to squeeze in ophthalmic products TOP20 list of preparations, the current market leader in the business for the United States Al build, market share of over 80% had earlier obtained approval of the domestic pharmaceutical enterprises, including the Hang Seng Nanjing, Beijing and Lunan pharmaceutical Department of En Lande Better Pharmaceuticals, Qilu Pharmaceuticals was approved according to 4 types of generics this time and was the first to pass the review.
Figure 3: Chengdu Shengdi Medicine declares a new clinical drug
Source: CDE official website
According to data from Menet.
com, the sales scale of terminal ophthalmic preparations in Chinese public medical institutions in 2019 has risen to nearly 7 billion yuan.
In 2020, 13 domestic new products will be approved for marketing (according to the date of approval), and they have been approved since 2021.
There are also 8 new products on the market.
With the continuous efforts of domestic pharmaceutical companies, the market for ophthalmic preparations is also growing.
com, the sales scale of terminal ophthalmic preparations in Chinese public medical institutions in 2019 has risen to nearly 7 billion yuan.
In 2020, 13 domestic new products will be approved for marketing (according to the date of approval), and they have been approved since 2021.
There are also 8 new products on the market.
With the continuous efforts of domestic pharmaceutical companies, the market for ophthalmic preparations is also growing.
Source: NMPA official website, CDE official website, Mi Nei.
com data
com data
The review data statistics are as of April 19, if there are any errors or omissions, please correct me.
